Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens.

Combe, B, Furst, DE, Keystone, EC et al. (5 more authors) (2016) Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens. Arthritis Care and Research, 68 (3). pp. 299-307. ISSN 2151-464X

Abstract

Metadata

Item Type: Article
Authors/Creators:
  • Combe, B
  • Furst, DE
  • Keystone, EC
  • van der Heijde, D
  • Luijtens, K
  • Ionescu, L
  • Goel, N
  • Emery, P
Copyright, Publisher and Additional Information:

(c) 2016, The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Dates:
  • Published: March 2016
  • Published (online): 23 February 2016
  • Accepted: 21 July 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 21 Jun 2016 13:20
Last Modified: 01 Jun 2023 15:58
Published Version: http://dx.doi.org/10.1002/acr.22676
Status: Published
Publisher: Wiley
Identification Number: 10.1002/acr.22676
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics